Working with FDA: Biological Products and Clinical Development IND Case Studies Karen D. Jones Chief, Project Management Staff Division of Biologic Oncology Products Office…

Slide 1Foucauldian Discourse Analysis (FDA) Willig (2008) Slide 2 What is the focus of FDA? How language shapes experience FDA is concerned with language and its role in…

Slide 1 DATA MONITORING COMMITTEES: A Regulator’s Perspective Mary A. Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research…

Slide 1 Clinical Review Process: An FDA Perspective Karen Midthun, M.D. Deputy Director of Medicine Center for Biologics Evaluation and Research FDA April 15, 2005 Slide…

World Health Organization International Biological Standards Elwyn Griffiths Biologics and Genetic Therapies Directorate WHOâS BIOLOGICAL STANDARDIZATION PROGRAMME Develops…

New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality…

World Health Organization International Biological Standards Elwyn Griffiths Biologics and Genetic Therapies Directorate WHOâS BIOLOGICAL STANDARDIZATION PROGRAMME Develops…

Slide 1 Foucauldian Discourse Analysis (FDA)   Willig (2008) What is the focus of FDA?   How language shapes experience FDA is concerned with language and its role in the…

bpac Dengue Virus and Its Risk to the U.S. Blood Supply Blood Products Advisory Committee December 14, 2010 Deborah R. Taylor, Ph.D. Division of Emerging Transfusion Transmitted…

SPRING 2013 SOUTH FLORIDA CHAPTER MS CONNECTION NEWSLETTER INSIDE THIS ISSUE 02 FDA APPROVED NEW ORAL THERAPY 14 MS GOLF TOURNAMENT SPECIAL RESEARCH EVENT: MS THROUGH ALL…